CN1768056A - 色烯酮吲哚 - Google Patents

色烯酮吲哚 Download PDF

Info

Publication number
CN1768056A
CN1768056A CNA2004800085714A CN200480008571A CN1768056A CN 1768056 A CN1768056 A CN 1768056A CN A2004800085714 A CNA2004800085714 A CN A2004800085714A CN 200480008571 A CN200480008571 A CN 200480008571A CN 1768056 A CN1768056 A CN 1768056A
Authority
CN
China
Prior art keywords
formula
compounds
compound
group
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800085714A
Other languages
English (en)
Chinese (zh)
Inventor
K·席曼
H·伯切尔
T·海因里希
G·霍尔策曼
C·范阿姆斯特丹
G·巴尔托谢克
J·莱布罗克
C·赛弗里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1768056A publication Critical patent/CN1768056A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CNA2004800085714A 2003-04-04 2004-03-08 色烯酮吲哚 Pending CN1768056A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10315285A DE10315285A1 (de) 2003-04-04 2003-04-04 Chromenonindole
DE10315285.7 2003-04-04

Publications (1)

Publication Number Publication Date
CN1768056A true CN1768056A (zh) 2006-05-03

Family

ID=32981019

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800085714A Pending CN1768056A (zh) 2003-04-04 2004-03-08 色烯酮吲哚

Country Status (18)

Country Link
US (1) US7968551B2 (enExample)
EP (1) EP1611126B1 (enExample)
JP (1) JP4740114B2 (enExample)
KR (1) KR20050119673A (enExample)
CN (1) CN1768056A (enExample)
AR (1) AR043834A1 (enExample)
AT (1) ATE446959T1 (enExample)
AU (1) AU2004226279B2 (enExample)
BR (1) BRPI0408467A (enExample)
CA (1) CA2520892C (enExample)
DE (2) DE10315285A1 (enExample)
DK (1) DK1611126T3 (enExample)
ES (1) ES2335665T3 (enExample)
MX (1) MXPA05010483A (enExample)
PL (2) PL1611126T3 (enExample)
PT (1) PT1611126E (enExample)
WO (1) WO2004087692A1 (enExample)
ZA (1) ZA200508922B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
CN104045608A (zh) * 2013-03-11 2014-09-17 天津药物研究院 一种取代哌嗪化合物及制备维拉佐酮中间体的方法
CN104059046A (zh) * 2013-03-18 2014-09-24 江苏恩华药业股份有限公司 黄酮类衍生物及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
CN104045608A (zh) * 2013-03-11 2014-09-17 天津药物研究院 一种取代哌嗪化合物及制备维拉佐酮中间体的方法
CN104045608B (zh) * 2013-03-11 2016-06-01 天津药物研究院有限公司 一种取代哌嗪化合物及制备维拉佐酮中间体的方法
CN104059046A (zh) * 2013-03-18 2014-09-24 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用

Also Published As

Publication number Publication date
PL377730A1 (pl) 2006-02-06
AU2004226279A1 (en) 2004-10-14
ZA200508922B (en) 2007-02-28
US20060258680A1 (en) 2006-11-16
ES2335665T3 (es) 2010-03-31
PT1611126E (pt) 2010-01-29
EP1611126B1 (de) 2009-10-28
AR043834A1 (es) 2005-08-17
KR20050119673A (ko) 2005-12-21
EP1611126A1 (de) 2006-01-04
BRPI0408467A (pt) 2006-04-04
DE502004010296D1 (de) 2009-12-10
JP4740114B2 (ja) 2011-08-03
PL1611126T3 (pl) 2010-02-26
AU2004226279B2 (en) 2010-10-28
US7968551B2 (en) 2011-06-28
CA2520892A1 (en) 2004-10-14
JP2006522034A (ja) 2006-09-28
DK1611126T3 (da) 2010-01-18
CA2520892C (en) 2012-08-21
WO2004087692A1 (de) 2004-10-14
DE10315285A1 (de) 2004-10-14
MXPA05010483A (es) 2005-11-16
ATE446959T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
CN1093127C (zh) 哌嗪衍生物
CN1229345C (zh) N－(吲哚羰基)哌嗪衍生物
CN1344265A (zh) 哌啶、四氢吡啶和哌嗪衍生物,它们的制备和用途
CN1123571C (zh) 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶
CN1653063A (zh) (s)－4－氨基－5－氯－2－甲氧基－n－[1－[1－(2－四氢呋喃羰基)－4－哌啶甲基]－4－哌啶基]苯甲酰胺及其制备方法、含有该化合物的药物组合物及其中间体
CN1437596A (zh) 苯基哌嗪基衍生物
WO2011002103A2 (en) A cycloalkane derivative
CN1437597A (zh) 取代的苯基－哌嗪衍生物及其制备和用途
CN1177847C (zh) 作为5－ht2a拮抗剂的噁唑烷酮类化合物
CN1729173A (zh) N－(吲哚乙基)环胺化合物
JP4740114B2 (ja) クロメノンインドール
JP2009504793A (ja) ドーパミンｄ３受容体の調節因子としてのアザビシクロ［３．１．０］ヘキシルフェニル誘導体
CN1434819A (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1805953A (zh) 用作血清素再摄取抑制剂的吲哚衍生物
CN1052864A (zh) 喹诺酮化合物及其制备方法
CN1503799A (zh) 抗抑郁的7,8-二氢-1,6,9-三氧杂-3-氮杂-环戊二烯并[a]萘的氮杂环基甲基衍生物
CN1372545A (zh) 吲哚衍生物
CN1178934C (zh) 苯并呋喃衍生物
CN1304409A (zh) 用于治疗抑郁症的吲哚－3－基－环己胺衍生物(5－ht1受体拮抗剂)
CN1139588C (zh) 新的氟化咪唑啉苯并二噁烷,其制备及其治疗用途
CN1439004A (zh) 用于治疗中枢神经系统疾病的吲哚衍生物
CN1043764C (zh) 作为5－ht1a拮抗剂的双环甲酰胺
CN1809574A (zh) 喹啉3－氨基苯并二氢吡喃衍生物
CN1445222A (zh) 苯并吡喃类化合物、其制备方法和用途
CN1224015A (zh) 双吲哚杂环化合物、制备方法及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication